Edition:
United Kingdom

Marinus Pharmaceuticals Inc (MRNS.OQ)

MRNS.OQ on NASDAQ Stock Exchange Global Market

7.89USD
15 Dec 2017
Change (% chg)

$-1.44 (-15.43%)
Prev Close
$9.33
Open
$9.43
Day's High
$9.45
Day's Low
$7.78
Volume
1,385,014
Avg. Vol
398,713
52-wk High
$9.86
52-wk Low
$0.82

Chart for

About

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral... (more)

Overall

Beta: --
Market Cap(Mil.): $220.52
Shares Outstanding(Mil.): 31.75
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Marinus Pharmaceuticals files for mixed shelf of up to $200 mln

* Marinus Pharmaceuticals Inc - files for a mixed shelf of up to $200 million - SEC filing‍​ Source text: [http://bit.ly/2z23P1a] Further company coverage:

31 Oct 2017

BRIEF-Marinus Pharmaceuticals qtrly loss per share $0.15‍​

* Marinus Pharmaceuticals provides business update and reports third quarter 2017 financial results

31 Oct 2017

BRIEF-Bain Capital Life Sciences Fund reports 14.4 pct passive stake in Marinus Pharmaceuticals

* Bain Capital Life Sciences Fund L.P reports 14.4 percent passive stake in Marinus Pharmaceuticals Inc as of Sept 19, 2017 - SEC filing Source text for Eikon: (http://bit.ly/2fUP6u2) Further company coverage:

28 Sep 2017

BRIEF-Marinus Pharmaceuticals announces pricing of public offering of common stock

* Marinus Pharmaceuticals announces pricing of public offering of common stock

15 Sep 2017

BRIEF-Marinus Pharmaceuticals announces public offering of common stock

* Marinus Pharmaceuticals Inc announces public offering of common stock

14 Sep 2017

BRIEF-Marinus announces successful clinical trial results

* Marinus announces successful clinical trial results and declares CDKL5 disorder its lead pediatric orphan epilepsy program for ganaxolone

11 Sep 2017

BRIEF-EecoR1 Capital reports 12.2 pct passive stake in Marinus Pharmaceuticals

* EecoR1 Capital LLC​ report a 12.2 percent passive stake in Marinus Pharmaceuticals Inc as of August 4, 2017 - SEC filing Source text: (http://bit.ly/2vMhmJe) Further company coverage:

08 Aug 2017

BRIEF-Marinus Pharmaceuticals posts quarterly loss of $0.21 per share

* Provides business update and reports second quarter 2017 financial results

01 Aug 2017

BRIEF-Marinus Pharmaceuticals says Granite Point reports a 9.75 percent passive stake in Marinus- SEC Filing

* Granite point capital management lp reports a 9.75 percent passive stake in marinus pharmaceuticals inc as of july 6, 2017 - sec filing Source text for Eikon: Further company coverage:

18 Jul 2017

BRIEF-Marinus Pharmaceuticals says James Flynn reports 9.98 percent passive stake in Marinus as of July 14, 2017 - sec filing

* James E. Flynn reports a 9.98 percent passive stake in Marinus Pharmaceuticals Inc as of July 14, 2017 - Sec Filing Source text for Eikon: Further company coverage:

17 Jul 2017

Earnings vs. Estimates